Whitehawk Therapeutics
WHWK
24 hedge funds and large institutions have $8.96M invested in Whitehawk Therapeutics in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 6 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
5% more capital invested
Capital invested by funds: $8.56M → $8.96M (+$408K)
0.06% more ownership
Funds ownership: 1.56% → 1.62% (+0.06%)
4% less funds holding
Funds holding: 25 → 24 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.56M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110K |
| 3 |
BlackRock
New York
|
+$73.6K |
| 4 |
Two Sigma Investments
New York
|
+$68K |
| 5 |
Renaissance Technologies
New York
|
+$63.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.4M |
| 2 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$45.2K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$21K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$19.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$11K |
WHWK Hedge Fund Activity: Q2 2019 in Review
24 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2019, worth a combined $8.96M — up 4.8% from $8.56M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of WHWK and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.56M. The largest seller was Artal Group, exiting entirely with an estimated $1.4M sold.
- 24 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2019, down from 25 in Q1 2019.
- Funds reported $8.96M of Whitehawk Therapeutics stock for Q2 2019, up 4.8% quarter-over-quarter.
- 5 funds opened new Whitehawk Therapeutics positions in Q2 2019 and 6 closed out, a net change of -1 holder.
- The largest Whitehawk Therapeutics buyer in Q2 2019 was Goldman Sachs, an estimated $1.56M added.
- The largest Whitehawk Therapeutics seller in Q2 2019 was Artal Group, an estimated $1.4M sold.
Based on aggregated 13F filings for Q2 2019.